News
Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following ...
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback